Pioglitazone Hydrochloride NEW

Factory Provide Raw Material Pioglitazone HCl CAS 112529-15-4 Pioglitazone Hydrochloride

Introduction

Product Name :  Pioglitazone Hydrochloride

Other name:5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzylidine]-2,4-thiazolidinedionehydrochloride;AD-4833;pioglitazone hcl;

CAS No.: 112529-15-4

Molecular Formula: C19H21ClN2O3S

Molecular Weight: 392.9

Specification:99%

Appearance: White powder or crystal 

Melting Point :193-194°C

Solubility :Soluble in water (<1 mg/ml at 25°C), DMF, methanol, ethanol (4 mg/ml at 25°C), and DMSO (79 mg/ml at 25°C).

Storage :Keep in dark place,Sealed in dry,Store in freezer, under -20°C

Pioglitazone is a new orally active thiazolidinedione (TZD) launched in the US for the treatment of  dependent diabetes mellitus (NIDDM). It can be synthesized in 4 steps, the last one transforming an alphabromoester into thiazolidine. As with other representatives in this class, it potently activates the nuclear receptor peroxisome proliferator-activated receptor gamma which is believed to be involved in the regulation of  resistance and adipogenesis. In several obese and obese diabetic animal models, treatment with Pioglitazone resulted in reductions in plasma glucose and serum lipids. In clinical studies, Pioglitazone at a once daily oral dose of 15-45 mg, as monotherapy or in combination with non-TZDs , was shown to significantly improve glycemic control in type-2 diabetes and demonstrated a beneficial effect on  resistance and other clinically relevant parameters as plasma levels of triglycerides or HDL-cholesterol. Pioglitazone is reported to be safe and well tolerated and is said to have a lower occurrence of hepatic toxicity as well as a low probability for drug interaction.

Application 

Pioglitazone is used to lower blood glucose levels in the treatment of diabetes mellitus type 2 (T2DM) either alone or in combination with a sulfonylurea, metformin, or insulin.The main study that looked at the medication, however, found no statistically significant difference in the main cardiovascular outcomes that were looked at.
The secondary outcome of death from all causes, myocardial infarction, and stroke were lower. Pioglitazone has also been used to treat non-alcoholic steatohepatitis (fatty liver), but this use is presently considered experimental.